activators that contain both basic helix-loop-helix and Per-ARNT-Sim domains, HIF-1α and HIF-1β. Once the two subunits dimerize, the complex then binds with its coactivators p300/CBP, which allow HIF to bind to DNA and act as a transcriptional regulator of a multitude of downstream hypoxiaresponsive genes. Increased HIF-1α activity leads to transcription of several critical angiogenic factors, including vascular endothelial growth factor (VEGF), nitric oxide synthase, and stromal cellderived factor-1. 1, 2 HIF-1β is a constitutively expressed protein that plays a role in many biological processes; however, HIF-1α is specific to hypoxia regulation. HIF-1α undergoes significant posttranslational modification; in particular, hydroxylation and phosphorylation, which controls the stability and activity of the HIF heterodimer. 3 Mitogen-activated protein kinase-mediated phosphorylation of HIF-1α occurs after stabilization of the protein under hypoxic conditions. Phosphorylation of specific serine residues, Ser-641/643, on HIF-1α augments its transcriptional activity because of improved HIF-1β dimerization and subsequent DNA binding and HIF-1α nuclear accumulation. 4, 5 The posttranslational hydroxylation of HIF-1α is under the control of a family of prolyl hydroxylases (prolyl hydroxylases 1, 2, and 3) and an asparaginyl hydroxylase known as factor inhibiting HIF-1α. These hydroxylases belong to a family of iron-dependent dioxygenases that require iron, oxygen, and 2-oxaloglutarate as cofactors for the hydroxylation process. Therefore, these enzymes are inactive in the absence of oxygen (e.g., under hypoxic conditions, in the presence of iron chelators such as deferoxamine, or in the presence of a 2-oxaloglutarate competitive inhibitor such as dimethyloxalylglycine). 6, 7 The oxygen-dependent degradation domain of HIF-1α contains two conserved proline residues, 564 and 402, that are hydroxylated by prolyl hydroxylases. Hydroxylation of HIF-1α occurs under normal oxygen tensions and provides a binding site for the von Hippel-Lindau protein, which mediates the ubiquitination and proteasomal degradation of HIF-1α protein. Because the prolyl hydroxylases require oxygen as a co-activator, their activity is inhibited under hypoxic conditions, leading to decreased HIF-1α hydroxylation, decreased von Hippel-Lindau protein-mediated ubiquitination and degradation, and increased HIF-1α protein stability. Loss or blockade of von Hippel-Lindau protein activity constitutively stabilizes HIF-1α protein under normoxic conditions. 1 In addition, hydroxylation of an asparagine residue (803) by factor inhibiting HIF-1α in the C-terminal transactivation domain of HIF-1α leads to inactivation of its transcriptional activity by preventing the recruitment and binding of the HIF-1α coactivators p300/CBP. [8] [9] [10] [11] These biochemical reactions provide us certain therapeutic strategies to promote HIF-1α stabilization and transactivation by the inhibition of prolyl hydroxylases and factor inhibiting HIF-1α activity.
Neovascularization, including vasculogenesis and angiogenesis, plays a critical role in the postnatal pathophysiology of ischemic disorders, tumor growth, wound healing, and diabetes. 12 Angiogenesis, the sprouting of new blood vessels from preexisting vessels, is the major mechanism underlying vascular remodeling in the adult. However, vasculogenesis has recently received considerable attention because the recruitment of bone marrow-derived endothelial progenitor cells may lead to novel therapeutic approaches. 13, 14 All forms of diabetes are characterized by chronic hyperglycemia-induced neovascular dysfunction, which contributes to impaired wound healing, impaired coronary collateral vessel development, and embryonic vasculopathy in pregnancies complicated by maternal diabetes. 15 Poorly controlled diabetes leads to peripheral vascular disease, with chronic ulcers and an increased rate of amputation. 16, 17 Four major mechanisms have been hypothesized to cause the hyperglycemia-induced vasculopathy seen in diabetic patients: increased polyol pathway flux, advanced glycosylation end-product formation, protein kinase C isoform activation, and hexosamine pathway flux. The common link among these four pathogenic mechanisms is the overproduction of reactive oxygen species by the mitochondrial electron-transport chain. 18 Many studies have shown that the iron chelator deferoxamine 19 scavenges oxygen free radicals and can reduce the oxidative stress in diabetic hyperglycemia.
Our previous studies have shown that hyperglycemia decreases the production of VEGF by fibroblasts in diabetic patients and mice under hypoxic condition. Moreover, chronic hyperglycemia inhibits HIF-1α DNA binding and transcriptional activity by interfering with interactions with the cofactor p300. 20 This study seeks to further evaluate the molecular mechanisms underlying hyperglycemia-induced HIF-1α dysfunction in vitro and in vivo and to explore potential therapeutic strategies using deferoxamine and dimethyloxalylglycine in chronic hyperglycemia.
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MATERIALS AND METHODS
Cell Culture
Mouse embryonic fibroblasts were generously provided by Dr. Karl Sylvester (Stanford University School of Medicine). All cells were cultured in Dulbecco's Modified Eagle Medium (Invitrogen Corp., Carlsbad, Calif.) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin and were used for experimentation after being passaged twice. For low-glucose culture, Dulbecco's Modified Eagle Medium with 5 mM d-glucose was used. For high-glucose culture, 30 mM d-glucose was used. Chronic hyperglycemia was performed for 4 weeks using a high-glucose Dulbecco's Modified Eagle Medium changed every other day. Deferoxamine and dimethyloxalylglycine concentrations (1-mM solutions) were used based on previously published data on in vitro and in vivo efficacy. 20, 21 All hypoxia treatments were performed at 1% oxygen for 16 hours in a BioSpherix hypoxia work station (BioSpherix, Redfield, N.Y.).
Western Blot
Cell nuclear protein extraction was performed with NE-PER nuclear and cytoplasmic extraction reagents (Pierce Biotechnology, Rockford, Ill.) according to the manufacturer's instructions. Next, 30 µg of protein was separated on a 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immobilized on a polyvinylidene difluoride membrane (Millipore Corp., Billerica, Mass.). The membranes were blotted with anti-HIF-1α (1:1000; Novus Biologicals, Inc., Littleton, Colo.) and anti-β-actin antibody (1:5000; Sigma-Aldrich, St. Louis, Mo.) at 4°C overnight. Secondary antibodies were either antirabbit immunoglobulin G (1:10,000; Amersham Biosciences Inc., Piscataway, N.J.) or anti-mouse immunoglobulin G (1:5000; Upstate Biotechnology, Inc., Lake Placid, N.Y.) and were incubated at room temperature for 30 minutes. Blots were detected with the ECL chemiluminescent reagent (Amersham Biosciences) for 5 minutes, and exposed to BioMax films (Eastman Kodak, Rochester, N.Y.) for 10 minutes.
HIF-1α Transactivity Reporter Assay
5HRE-Luc (a kind gift from Dr. Amato Giaccia, Stanford University School of Medicine) is a luciferase reporter driven by a hypoxia-inducible promoter containing five tandem repeats of the hypoxia-response element. pGL3 (Promega, Madison, Wis.) was used as a hypoxia-response element luciferase control. The DNA plasmids were transfected into fibroblasts according to the manufacturer's instructions using the Lipofectamine Plus reagent (Invitrogen). A Renilla luciferase expression vector (Promega) was cotransfected to adjust for variation in transfection efficiency. The luciferase assays were performed using Dual-Luciferase reporter system reagents (Promega) in a Monolight 3010 luminometer (BD Biosciences Pharmingen, San Diego, Calif.), and each reporter assay was repeated at minimum in triplicate.
Mammalian Two-Hybrid Assay
pVP16-C/H1 containing p300 C/H1 domain and pGal4-HIF-1α (776 to 826) including HIF-1α C-terminal activation domain were generous gifts from Dr. Eric Huang (University of Utah). A CheckMate pG5luc, pBIND, and pACT were purchased from Promega and used as controls. The same transient transfection reagents and luciferase assay were used as described above.
Hydrogen Peroxide Assay
A hydrogen peroxide assay (Amplex Red; Invitrogen) was used to determine the presence of hydrogen peroxide according to the manufacturer's instruction. Briefly, working solutions were made fresh for each assay and added to wells to a final volume of 100 µl. Samples were incubated for 30 minutes in the dark in a 96-well black plate with clear well bottoms. Fluorescence readings were obtained in a fluorescence reader (PerkinElmer, Inc., Wellesley, Mass.) with excitation at 485 nm and emission at 580 nm. Wells were counted in triplicate.
Animals
All experiments were performed using protocols approved by Stanford University Animal Care and Use Committee guidelines. Aged (21 months; National Institute on Aging, Bethesda, Md.) and diabetic (12 weeks, BKS.Cg-M+/+Lepr db /J; The Jackson Laboratory, Bar Harbor, Me.) C57BL/6J mice were used for in vivo wound healing experiments. All experiments were conducted in accordance with Stanford University Institutional Animal Care and Use Committees.
In Vivo Excisional Wound Model
To evaluate the effect of deferoxamine and dimethyloxalylglycine on murine wound healing, paired 6-mm full-thickness cutaneous wounds
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were created on the dorsa of mice as described previously. 22 Each wound was held open by donutshaped silicone rings fastened with 6-0 nylon sutures to prevent wound contraction. Aged and diabetic mice were randomized into three treatment groups: daily application of 10 μl of deferoxamine or dimethyloxalylglycine drip-on (1 mM solutions) and phosphate-buffered saline vehicle control (n = 4 per group). All wounds were covered with an occlusive dressing (Tegaderm; 3M, St. Paul, Minn.). Digital photographs were taken on days 0, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21. Wound area was measured using ImageJ software (National Institutes of Health, Bethesda, Md.). On complete healing, wounds were harvested and processed for neovascularization assessment by means of CD31 immunohistochemistry.
Statistical Analysis
Responses of control and treatment in each experiment were compared using an unpaired t test. All error bars represent the standard error of the mean.
RESULTS
Hydroxylase Inhibition with Dimethyloxalylglycine Normalizes HIF-1α Expression and Phosphorylation in Hypoxia
Dimethyloxalylglycine is known to inhibit factor inhibiting HIF-1α and the prolyl hydroxylases through competitive inhibition of 2-oxoglutarate and thus may represent an attractive therapeutic agent to attenuate HIF-1α impairment in diabetes. 23 Here, we compared HIF-1α expression, phosphorylation, transcriptional activity, and interaction with p300 between mouse embryonic fibroblasts cultured with and without dimethyloxalylglycine treatment. Consistent with its function as an inhibitor of prolyl hydroxylases, we found that dimethyloxalylglycine significantly increased HIF-1α protein stability across all conditions (Fig. 1, above) .
However, we previously showed that impaired activity, rather than stability, is the main mechanism underlying HIF dysfunction. 20 Therefore, to restore HIF function, dimethyloxalylglycine needs to increase not only HIF expression but also its hypoxic transactivity under hyperglycemic conditions. As such, we examined the effects of dimethyloxalylglycine on HIF-1α transactivity using a mammalian two-hybrid luciferase reporter system. As expected, dimethyloxalylglycine treatment significantly increased luciferase activity in cells cultured under normal glucose conditions in normoxia, and this effect was also observed in hypoxia (Fig. 1, below, left) . Interestingly, when dimethyloxalylglycine was applied to cells cultured under high-glucose conditions, normoxic HIF-1α/p300 binding increased significantly, approximating that of untreated cells in hypoxia. However, under hypoxic high-glucose conditions, dimethyloxalylglycine treatment failed to increase HIF-1α binding above baseline.
Finally, to determine the effect of dimethyloxalylglycine-mediated hydroxylase inhibition on HIF-1α's activity as a transcriptional regulator, mouse embryonic fibroblasts treated with dimethyloxalylglycine were analyzed using a hypoxiaresponse element luciferase assay as described previously. 20 Similar to the mammalian two-hybrid results above, dimethyloxalylglycine treatment significantly increased luciferase activity in cells cultured under normal glucose conditions in both normoxia and hypoxia, and high-glucose conditions under normoxia (Fig. 1, below, right) . However, under hypoxic high-glucose conditions, dimethyloxalylglycine treatment failed to increase hypoxia-response element activity above baseline. This suggests that although dimethyloxalylglycine is able to partially reverse the hyperglycemia-induced HIF dysfunction, a full recovery to normoglycemic activity is not achieved. Furthermore, as the latter culture conditions (hypoxic, elevated glucose) most closely mirror those of ischemic diabetic wounds, this suggests that dimethyloxalylglycine may not be an ideal candidate for diabetic wound healing. Considered together, these data indicate that dimethyloxalylglycine-induced inhibition of HIF-1α hydroxylation improves its biological function by increasing HIF-1α phosphorylation and improving its interaction with its coactivator p300; however, these effects are significantly reduced under hypoxic, hyperglycemic conditions.
Deferoxamine Improves HIF-1α Function under Hypoxic and Hyperglycemic Conditions
Deferoxamine is an iron chelator that stabilizes HIF-1α by scavenging oxygen free radicals and inhibiting HIF-1α hydroxylation through iron chelation. 20 We have previously shown that deferoxamine increases HIF-1α expression in both high-glucose and normal-glucose culture. 20 Here, we evaluated the effect of deferoxamine treatment on HIF-1α transactivation and HIF-1α/p300 binding. Using a hypoxia-response element luciferase reporter assay, we found that deferoxamine significantly increased normoxic HIF transactivation in mouse embryonic fibroblasts under both high-glucose and normal-glucose conditions (Fig. 2, above, left) . Unlike with dimethyloxalylglycine, we also found that deferoxamine treatment significantly increased HIF transactivation under hypoxia for cells in high-glucose and normal-glucose culture. HIF-1α/p300 binding was assessed using a mammalian two-hybrid luciferase reporter system, and we found that deferoxamine treatment significantly increased HIF-1α binding under all culture conditions, including hypoxic and high-glucose (Fig. 2, above, right) . These findings, in conjunction with our dimethyloxalylglycine data above, suggest that deferoxamine and dimethyloxalylglycine impact HIF-1α activity by means of separate mechanisms, and that although the ability of dimethyloxalylglycine to inhibit prolyl hydroxylase activity does improve HIF-1α protein expression, it is not as effective as deferoxamine in its attenuation of HIF-1α activity.
Because reactive oxygen species are believed to be responsible for many of the complications in chronic hyperglycemia, we also evaluated whether deferoxamine could reduce reactive oxygen species generated by high glucose. Using a hydrogen peroxide assay, we found that deferoxamine significantly attenuated the hyperglycemia-associated increase in reactive oxygen species levels under hypoxic high-glucose conditions, normalizing hydrogen peroxide levels to that of cells cultured under normal-glucose conditions (Fig. 2, below) . These data are consistent with deferoxamine's proposed mechanism of improving HIF-1α biological function through scavenging oxygen free radicals. Fig. 1 . Deferoxamine (DFO) increased HIF-1α activity and decreased reactive oxygen species in mouse embryonic fibroblasts in vitro, whereas dimethyloxalylglycine (DMOG) was unable to correct the high-glucose effects. (Above, left) HIF-1α Western blots for mouse embryonic fibroblasts with and without dimethyloxalylglycine treatment cultured under low-glucose normoxic (LN), high-glucose normoxic (HN), low-glucose hypoxic (LH), or high-glucose hypoxic (HH) conditions. Dimethyloxalylglycine increases HIF-1α stabilization in all conditions. (Above, right) Quantification of Western blots (WB). (Below, left) Mammalian two-hybrid luciferase activity measured in mouse embryonic fibroblasts with or without dimethyloxalylglycine treatment under various culture conditions. Dimethyloxalylglycine is unable to correct the high-glucose effects. (Below, right) Hypoxia-response element luciferase activity compared between mouse embryonic fibroblasts with and without dimethyloxalylglycine treatment under various culture conditions. Dimethyloxalylglycine is unable to correct the high-glucose effects. All measurements in below were normalized to that of control cells cultured under low-glucose normoxic conditions. All measurements in above, left and above, right were normalized to that of control cells cultured under low-glucose normoxic conditions (n = 3; *p < 0.05; **p < 0.01; ***p < 0.001). All data are means ± 1 SEM.
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Deferoxamine, but Not Dimethyloxalylglycine, Enhances Wound Healing in Diabetic Mice
Given our in vitro observations on the efficacy of dimethyloxalylglycine and deferoxamine at attenuating the diabetes-induced impairments in HIF-1α activity, we explored the therapeutic potential of these molecules in diabetic wound healing. Splinted excisional wounds were created on the dorsum of type 2 diabetic mice (db/db) as described previously, 24 and mice received daily treatment with either 10 μl of 1 mM dimethyloxalylglycine solution, 10 μl of 1 mM deferoxamine solution, or saline. Wounds were monitored and photographed every other day until closure (Fig. 3, above) . Deferoxamine-treated wounds displayed significantly accelerated healing from day 7 onward and healed significantly faster than control-treated wounds (15 days versus 20 days; p < 0.05), whereas dimethyloxalylglycine-treated wounds exhibited no improvement compared with controls (18.7 days versus 20 days; p = 0.39) (Fig. 3, center) . These results are consistent with our in vitro findings on the differential efficacy of deferoxamine over dimethyloxalylglycine in reversing the effects of chronic hyperglycemia and could be further confirmed on a histologic level with an increase of neovascularization exclusive to the deferoxamine treatment group (Fig. 3,  below) .
Both Dimethyloxalylglycine and Deferoxamine Enhance Wound Healing in Aged Mice
To determine whether our observations above were specific to diabetes or were more broadly applicable to states of impaired wound healing, we compared the efficacy of dimethyloxalylglycine and deferoxamine in healing wounds from aged mice. Advanced age, like diabetes, is associated with elevated levels of prolyl hydroxylases, attenuated HIF-1α function, and impaired wound (Above) Luciferase activity measured in mouse embryonic fibroblasts with or without deferoxamine treatment cultured under low-glucose normoxic, high-glucose normoxic, low-glucose hypoxic, or high-glucose hypoxic conditions. Hypoxia-response element luciferase activity measured in mouse embryonic fibroblasts is significantly increased with deferoxamine treatment under all culture conditions. Mammalian two-hybrid luciferase activity mouse embryonic fibroblasts is significantly increased with deferoxamine treatment under all culture conditions. (Below) The fluorescence measurements at 485 nm (excitation) and 580 nm (emission) are detected using a hydrogen peroxide reporter assay. Deferoxamine significantly reduces reactive oxygen species generated by high glucose (n = 3; *p < 0.05; **p < 0.01; ***p < 0.001). Fig. 3 . Deferoxamine (DFO) but not dimethyloxalylglycine (DMOG) enhances diabetic wound healing in vivo. (Above and center, left) Gross appearance and area measurements of diabetic excisional murine wounds treated with dimethyloxalylglycine and deferoxamine. Application of deferoxamine resulted in significantly accelerated wound healing from day 7 on compared with wounds treated with dimethyloxalylglycine or phosphate-buffered saline control (CTRL). (Center, right) Application of deferoxamine resulted in an accelerated time to wound closure compared with wounds treated with dimethyloxalylglycine or phosphate-buffered saline control. #Statistically significant differences in wound closure time between deferoxamine versus dimethyloxalylglycine and phosphate-buffered saline control groups. (Below) CD31 immunostaining and quantification were assessed on complete healing (n = 4). Scale bar = 50 µm. All data are means ± 1 SEM (*p ≤ 0.05). Scale bar = 100 µm.
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healing, making it an ideal candidate for evaluating dimethyloxalylglycine and deferoxamine. As above, splinted excisional wounds were created on the dorsa of 21-month-old C57 black 6 mice, and mice received daily treatment with either 10 μl of 1 mM dimethyloxalylglycine solution, 10 μl of 1 mM deferoxamine solution, or saline. Wounds were monitored and photographed every other day until closure (Fig. 4, above) . Both deferoxamine-treated wounds and dimethyloxalylglycinetreated wounds healed significantly faster than control-treated wounds: 11.7 days versus 15 days (p < 0.05) and 12 days versus 15 days (p < 0.05), respectively (Fig. 4, center) . This could also be confirmed histologically by means of endothelial cell-specific CD31 immunostaining, illustrating significantly higher levels of neovascularization in both treatment groups (Fig. 4, below) . This suggests that the differential efficacy of deferoxamine versus dimethyloxalylglycine may be tied specifically to the pathophysiology of diabetes.
In summary, deferoxamine stabilizes HIF-1α expression, improves HIF-1α activity as a transcriptional regulator, and facilitates the interaction between HIF-1α and p300 in hypoxic and hyperglycemic states in vitro. The effects of dimethyloxalylglycine, in contrast, are significantly blunted under hyperglycemic hypoxic conditions. In vivo, both dimethyloxalylglycine and deferoxamine enhanced wound healing in aged mice, stimulating angiogenesis, but only deferoxamine universally augmented wound healing in the setting of both advanced age and diabetes. Our data suggest significant therapeutic potential for topical deferoxamine treatment in ischemic and diabetic diseases.
DISCUSSION
Numerous studies have demonstrated that hyperglycemia and hypoxia play important roles in diabetic vasculopathy, [25] [26] [27] [28] neuropathy, 29, 30 and retinopathy. 31, 32 The common links among these studies are HIF-1α dysfunction and VEGF reduction leading to impaired healing in diabetic individuals. Others have attempted to improve diabetic wound healing by replacing single cytokines such as VEGF, with only limited success. This suggests that defective diabetic neovascularization is associated with a more global HIF-1α defect rather than just its effect on VEGF production. However, the mechanisms of hyperglycemia-induced HIF-1α dysfunction remain unclear and, to some extent, controversial. To have a significant clinical impact on correcting diabetic vasculopathy, a better understanding of the HIF-1α defect must be elucidated. Here, we further this knowledge and suggest a significant therapeutic method for achieving this goal.
Aging results in profound changes in metabolic and repair mechanisms throughout the entire organism, impairing its natural regenerative capacity. 33, 34 Aging skin displays a phenotype characterized by atrophic dermal matrix with increased wrinkle formation and compromised wound healing. 35, 36 To heal adequately, a dynamic sequence of interactions between several skin cell types, the extracellular matrix, and numerous cytokines is required. 37 With advanced age, pathologic changes of these processes occur and result in impaired tissue repair through insufficient neovascularization, stromal deposition, and epithelialization. [38] [39] [40] [41] [42] On a molecular level, aging is characterized by a destabilization of HIF-1α by means of enhanced activity of its degrading enzyme prolyl hydroxylase-2, 39, 43 resulting in impaired release of growth factors. Recent studies from our group showed that fibroblast-specific deletion of HIF-1α critically impairs murine cutaneous neovascularization and wound healing and that short hairpin RNA silencing of prolyl hydroxylase-2 improves it. 44, 45 It could be further demonstrated that a loss of epidermal HIF-1α expression accelerates skin aging and affects reepithelialization. 46 In addition, evidence is accumulating that the dysfunctions associated with advanced age are linked to the effects of oxidative stress. [47] [48] [49] Reactive oxygen species accumulate in aged tissues because of a reduced antioxidant activity of aged cells, leading to reduced neovascularization, impaired fibroblast proliferation, and increased neutrophil recruitment. 50 However, our findings showing a comparable efficacy of dimethyloxalylglycine, which has no antioxidative effect, 20 and deferoxamine in aged wound healing, suggest that restoration of HIF-1α levels rather than reduction of reactive oxygen species stress is the dominant mechanism accelerating regeneration of aged tissues.
Dimethyloxalylglycine is a 2-oxoglutarate analogue, and its function results from competitive inhibition of 2-oxoglutarate which is attacked by ferric-superoxide species and generates carbon dioxide and succinate during factor inhibiting HIF-1α hydroxylation reactions. 6 In diabetes, high-glucose oxidation enriches the tricarboxylic acid cycle and increases metabolic byproducts, including 2-oxoglutarate. 18 Therefore, we hypothesize that dimethyloxalylglycine competitive inhibition is attenuated by excess endogenous Gross appearance and area measurements of aged excisional murine wounds treated with deferoxamine and dimethyloxalylglycine. Application of both dimethyloxalylglycine and deferoxamine resulted in significantly accelerated wound healing from day 9 on compared with wounds treated with phosphate-buffered saline control (CTRL). (Center, right) Application of deferoxamine and dimethyloxalylglycine resulted in an accelerated time to wound closure compared with wounds treated with phosphatebuffered saline control. #Statistically significant differences in wound closure time between deferoxamine and dimethyloxalylglycine treatment versus the phosphate-buffered saline control group. (Below) CD31 immunostaining and quantification were assessed on complete healing (n = 4). Scale bar = 50 µm. All data are means ± 1 SEM (*p ≤ 0.05). Scale bar = 100 µm.
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Deferoxamine has been the standard ironchelating therapy for transfusion-related siderosis for 30 years, and has improved the life expectancy and quality of life for patients with thalassemia major. 51, 52 Cell damage associated with iron overload arises from the accumulation of cytotoxic iron pools that promote production of reactive oxygen species exceeding intrinsic cellular defense capacities. 53 An intrinsic interaction exists between iron metabolism and glucose homeostasis, where iron affects glucose metabolism and glucose impinges on several iron metabolic pathways. Oxidative stress and inflammatory cytokines influence these relationships, amplifying and potentiating the initiated events. 54 Iron depletion has been beneficial in endothelial dysfunction and coronary heart disease in diabetes. 19, 55, 56 In our present studies, deferoxamine dramatically reduced reactive oxygen species induced by chronic hyperglycemia, which may account for the rescued phenotype in diabetic ischemia. As expected, deferoxamine improved HIF-1α function and angiogenesis both in vitro and in vivo.
During normal glucose and hypoxia conditions, HIF-1α is phosphorylated and facilitated to heterodimerize with HIF-1β. At the same time, low oxygen tension prevents HIF-1α from hydroxylation by factor inhibiting HIF-1α, and thus p300 and CBP are easily recruited to activate the transcriptional machinery. However, chronic hyperglycemia increases intracellular reactive oxygen species, dephosphorylates HIF-1α, and increases factor inhibiting HIF-1α mediated hydroxylation. This results in HIF-1α dissociation from HIF-1β and p300, which impairs HIF-1α activity as a transcriptional regulator of hypoxia-responsive genes, leading to poor neovascularization and wound healing. Both deferoxamine and dimethyloxalylglycine inhibit factor inhibiting HIF-1α activity; in addition, deferoxamine decreases oxygen free radicals, inferring a cytoprotective effect, and dimethyloxalylglycine increases HIF-1α phosphorylation, which augments HIF-1α transcriptional function.
Limitations of our study include the lack of a complete dose-response evaluation of deferoxamine or dimethyloxalylglycine administration. Although we have used a previously validated dosage regimen for our in vitro and in vivo studies,
